Monoclonal RhD prophylaxis: high time to evaluate efficacy
Monoclonal RhD prophylaxis: high time to evaluate efficacy
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
If left untreated, HDFN can result in severe anaemia, jaundice, and even severe brain damage (ie, kernicterus) and death. Since the 1960s, screening for the RhD blood group antigen and the administration of rhesus immunoprophylaxis (RhIG) to RhD-negative pregnant women has substantially decreased rhesus disease in high-income countries. Before the...
Alternative Titles
Full title
Monoclonal RhD prophylaxis: high time to evaluate efficacy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2937335758
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2937335758
Other Identifiers
ISSN
0140-6736,1474-547X
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(23)01888-3
